AXNX News and Press, Axonics Modulation Technologies Inc. From 09/02/20

Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, will host a webinar on September 9 during which principal inv...

Axonics Modulation Technologies, Inc. (AXNX) Q2 2020 Earnings Conference Call August 6, 2020 16:30 ET Company Participants Neil Bhalodkar - Investor Relations Raymond Cohen - Chief Executive Officer Dan Dearen - President & Chief Financial Officer Conference Call Participa...

Axonics Modulation Technologies (NASDAQ: AXNX ) : Q2 GAAP EPS of -$0.54 beats by $0.06 . Revenue of $15.2M (+920.1% Y/Y) beats by $10.14M . Press Release More news on: Axonics Modulation Technologies, Inc., Earnings news and commentary, Healthcare stocks news,

Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today reported financial results for the second quarter 2020 ...

Axonics Modulation Technologies (NASDAQ: AXNX ) announces positive results from a clinical study, ARTISAN-SNM , evaluating the Axonics r-SNM system in 129 patients with urinary urgency incontinence. More news on: Axonics Modulation Technologies, Inc., Healthcare stocks news, Read ...

Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today announced completion of 2-year follow-ups and topline c...

Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, will report financial results for the second quarter of 2020 ...

Axonics Modulation Technologies (NASDAQ: AXNX ) reports preliminary Q2 revenue and provided an operational update. More news on: Axonics Modulation Technologies, Inc., Healthcare stocks news, Read more ...

Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today reported preliminary unaudited second quarter 2020 reve...

The FDA has approved Axonics Modulation Technologies' (NASDAQ: AXNX ) supplemental marketing application for 3T full-body magnetic resonance imaging (MRI) conditional labeling for the Axonics r-SNM System. More news on: Axonics Modulation Technologies, Inc., Healthcare stocks news, Stock...